Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] The company operates in a highly competitive and fragmented segment with many players around. The sudden boost in its bottom line for 9M-FY23 raised eyebrows and concern over sustainability going forward. Based on such super earnings, the issue appears greedily priced, while based on its track records, it appears exorbitantly priced. There is no harm in skipping this pricey issue. Read detail review...
Cell Point (India) Limited peer comparison with similar listed entities. () (As on June 09, 2023)
| Company Name | EPS (Rs) | NAV (per share) (Rs) | P/E (x) | RoNW (%) |
|---|---|---|---|---|
| EPS Basic | ||||
| Cell Point (India) Limited | 14.47 | 117.45 | 6.91 | 12.32 |
| Bhatia Communications & Retail (India) Ltd | 0.42 | 3.69 | 44.82 | 11.40 |
| Fone4 Communications (India) Ltd | 1.71 | 8.87 | 3.32 | 8.50 |
| Jay Jalaram Technologies Ltd | 7.36 | 39.40 | 7.17 | 8.61 |
Notes:
Cell Point IPO Reviews, analysis and views by popular members. Read Cell Point (India) Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
RHP